- Home
- SUPN vs IRON Comparison
SUPN vs IRON Comparison
Compare SUPN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- IRON
- Stock Information
- Founded
- SUPN 2005
- IRON 2017
- Country
- SUPN United States
- IRON United States
- Employees
- SUPN N/A
- IRON N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- IRON Health Care
- Exchange
- SUPN Nasdaq
- IRON Nasdaq
- Market Cap
- SUPN 1.9B
- IRON 2.1B
- IPO Year
- SUPN 2012
- IRON N/A
- Fundamental
- Price
- SUPN $33.56
- IRON $59.35
- Analyst Decision
- SUPN Hold
- IRON Strong Buy
- Analyst Count
- SUPN 2
- IRON 12
- Target Price
- SUPN $36.00
- IRON $92.08
- AVG Volume (30 Days)
- SUPN 681.6K
- IRON 345.9K
- Earning Date
- SUPN 08-05-2025
- IRON 08-11-2025
- Dividend Yield
- SUPN N/A
- IRON N/A
- EPS Growth
- SUPN N/A
- IRON N/A
- EPS
- SUPN 1.11
- IRON N/A
- Revenue
- SUPN $667,997,000.00
- IRON N/A
- Revenue This Year
- SUPN N/A
- IRON N/A
- Revenue Next Year
- SUPN $15.74
- IRON N/A
- P/E Ratio
- SUPN $30.78
- IRON N/A
- Revenue Growth
- SUPN 11.82
- IRON N/A
- 52 Week Low
- SUPN $27.05
- IRON $30.82
- 52 Week High
- SUPN $40.28
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- SUPN 57.11
- IRON 60.45
- Support Level
- SUPN $32.94
- IRON $58.63
- Resistance Level
- SUPN $34.21
- IRON $60.95
- Average True Range (ATR)
- SUPN 1.06
- IRON 2.13
- MACD
- SUPN 0.04
- IRON -0.08
- Stochastic Oscillator
- SUPN 56.90
- IRON 57.50
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.